| S2745 |
CHIR-98014 |
CHIR-98014 is a potent GSK-3α/β inhibitor with IC50 of 0.65 nM/0.58 nM, with the ability to distinguish GSK-3 from its closest homologs Cdc2 and ERK2. |
Pan |
GSK-3α, IC50: 0.65 nM |
| S7063 |
LY2090314 |
LY2090314 is a potent GSK-3 inhibitor for GSK-3α/β with IC50 of 1.5 nM/0.9 nM; may improve the efficacy of platinum-based chemotherapy regimens. Phase 2. |
Pan |
GSK-3α, IC50: 1.5 nM |
| S7145 |
AZD1080 |
AZD1080 is a selective, orally active, brain permeable GSK3 inhibitor, inhibits human GSK3α and GSK3β with Ki of 6.9 nM and 31 nM, respectively, shows >14-fold selectivity against CDK2, CDK5, CDK1 and Erk2. |
Pan |
GSK-3α, IC50: 6.9 nM |
| S2924 |
CHIR-99021 (CT99021) HCl |
CHIR-99021 (CT99021) HCl is hydrochloride of CHIR-99021, which is a GSK-3α/β inhibitor with IC50 of 10 nM/6.7 nM; ability to distinguish between GSK-3 and its closest homologs Cdc2 and ERK2. |
Pan |
GSK-3α, IC50: 10 nM |
| S1075 |
SB216763 |
SB216763 is a potent and selective GSK-3 inhibitor with IC50 of 34.3 nM for GSK-3α and equally effective at inhibiting human GSK-3β. |
Pan |
GSK-3α, IC50: 34.3 nM |
| S2729 |
SB415286 |
SB415286 is a potent GSK3α inhibitor with IC50/Ki of 78 nM/31 nM with equally effective inhibition of GSK-3β. |
Pan |
GSK-3α, IC50: 78 nM |